ライフサイエンスコーパス: sphingosine-1-phosphate

1 of long-chain base phosphates (LCB-Ps, e.g., sphingosine-1-phosphate).

2 s observed in response to phorbol esters and sphingosine 1-phosphate.

3 of sphingosine and its bioactive metabolite, sphingosine 1-phosphate.

4 e kinase to produce the prosurvival molecule sphingosine-1-phosphate.

5 ut it was recruited following treatment with sphingosine-1-phosphate.

6 Amiselimod is an oral selective modulator of sphingosine 1-phosphate 1 (S1P1) receptor, which is bein

7 ion of mice and ferrets by administration of sphingosine-1-phosphate 1 receptor (S1P1R) agonists.

8 against neural injury via modulation of the sphingosine-1-phosphate 1 receptor (S1PR1).

9 Earlier we reported that modulation of sphingosine-1-phosphate-1 receptor (S1P1R) signaling pro

10 Sphingosine-1-phosphate, a bioactive sphingolipid metabo

11 inducible gene responsible for generation of sphingosine-1-phosphate, a critical lipid signaling mole

12 and is the major cell type supplying plasma sphingosine-1-phosphate, a signaling lipid regulating mu

13 Osteoclast-derived sphingosine-1-phosphate acts in paracrine to promote bon

14 Finally, we have shown that sphingosine 1-phosphate, an endogenous microglial signal

15 hereby controlling production of endothelial sphingosine 1-phosphate and autocrine, G protein-coupled

16 We identify activator sphingosine 1-phosphate and inhibitor DCPIB as chemical

17 catalyze the conversion of sphingosine into sphingosine 1-phosphate and play a key role in lipid sig

18 mmatory HDL particles, and low HDL levels of sphingosine-1-phosphate and apolipoprotein A-I were asso

19 Mechanistically, Pggt1b bridges sphingosine-1-phosphate and chemokine-induced migratory

20 vitro chemotaxis to chemoattractants such as sphingosine-1-phosphate and CXCL12.

21 phingosine) and sphingoid base-1-phosphates (sphingosine-1-phosphate and dihydrosphingosine-1-phospha

22 ressing podocytes had higher basal levels of sphingosine-1-phosphate and maintained basal ceramide le

23 Thus, sphingosine-1-phosphate and SphK2 play specific roles in

24 ctive sphingolipid metabolite sphingosine to sphingosine-1-phosphate, and suggested a role for sphing

25 ion include thrombin, lysophosphatidic acid, sphingosine-1-phosphate, and thromboxane A2.

26 application of fingolimod, an established SK/sphingosine-1-phosphate antagonist already in clinical u

27 matory index; phospholipase A2 activity; and sphingosine-1-phosphate, apolipoproteins A-I and A-IV, s

28 ix lipids, especially the ceramide-generated sphingosine 1-phosphate, are the messengers that the ski

29 lipid metabolites, particularly ceramide and sphingosine-1-phosphate, are signalling molecules that r

30 mmation involves the sphingosine kinase (SK)/sphingosine-1-phosphate axis.

31 immediate relevance for our understanding of sphingosine-1-phosphate biosynthesis, signaling, and deg

32 lysophosphatidic acid, phosphatidic acid, or sphingosine-1-phosphate but surprisingly not for the nat

33 ortance of sphingosine and its conversion to sphingosine-1-phosphate by SphK1 in endocytic membrane t

34 nanoparticles) containing elevated levels of sphingosine-1-phosphate, CCL20 and prostaglandin E2 (PGE

35 mide species but decreased sphingomyelin and sphingosine-1-phosphate concentrations.

36 We demonstrate the biological effect of sphingosine-1-phosphate contained in IDENs on tumour gro

37 reased cellular ceramide, sphingomyelin, and sphingosine-1-phosphate content.

38 we demonstrate that the main product of SK1, sphingosine-1-phosphate, controls the migration of intra

39 viously shown that sphingolipid signaling by sphingosine 1-phosphate decreases basal P-glycoprotein t

40 se from acidic stores that is independent of sphingosine 1-phosphate, extracellular and ER calcium le

41 ter than 50% reduction after incubation with sphingosine 1-phosphate, FTY720, or other sphingosine 1-

42 (SGPL1)-a key enzyme for the creation of the sphingosine-1 phosphate gradient, which is relevant to t

43 Sphingosine 1-phosphate has an important role in kidney

44 ngolipid metabolism, especially ceramide and sphingosine 1-phosphate, have been linked to colon cance

45 affic elicited by nonrelated agents, such as sphingosine 1-phosphate (i.e., transient alpha1B-AR-Rab5

46 expression was increased by cell stretch and sphingosine 1-phosphate in a RhoA-dependent manner, and

47 , which phosphorylate sphingosine to produce sphingosine 1-phosphate, in kidney fibrosis induced by f

48 e with the bioactive sphingolipid metabolite sphingosine-1-phosphate intertwined with those of my fam

49 Sphingosine 1-phosphate is a bioactive sphingolipid medi

50 ncreased cellular ceramide levels, decreased sphingosine 1-phosphate levels, and acted synergisticall

51 nt drop in SMPDL3b protein, sphingosine, and sphingosine-1-phosphate levels.

52 1 has emerged as an important determinant of sphingosine-1-phosphate lung levels, which, when aberran

53 iant, we describe the novel interaction with sphingosine 1-phosphate lyase (SGPL1)-a key enzyme for t

54 neumophila translocates the effector protein sphingosine-1 phosphate lyase (LpSpl) to target the host

55 pound RBM10-8 can irreversibly inhibit human sphingosine-1-phosphate lyase (hS1PL) while behaving als

56 rome caused by loss-of-function mutations in sphingosine-1-phosphate lyase (SGPL1).

57 and demonstrate that inhibiting the enzyme, sphingosine-1-phosphate lyase 1 (SPL), has neuroprotecti

58 he expression of sphingosine kinase 1 and 2, sphingosine-1-phosphate lyase 1, and sphingosine-1-phosp

59 omal interacting molecule-1 (STIM1), whereas sphingosine-1-phosphate-mediated enhancement of endothel

60 , 0.58; 95% CI, 0.40-0.83) and low levels of sphingosine-1-phosphate (OR(1SD), 0.70; 95% CI, 0.52-0.9

61 capacity (OR(1SD), 0.33; 95% CI, 0.18-0.61), sphingosine-1-phosphate (OR(1SD): 0.60; 95% CI: 0.40-0.8

62 edicts that these variants affect binding of sphingosine-1-phosphate (p.Arg108Pro) and G protein dock

63 ablished that fingolimod, a modulator of the sphingosine-1-phosphate pathway, restrains the egress of

64 ls by activation of the sphingosine kinase-1/sphingosine-1-phosphate pathway, resulting in improvemen

65 and 2, sphingosine-1-phosphate lyase 1, and sphingosine-1-phosphate phosphatase 1 in normal human li

66 Sphingosine-1-phosphate phosphatase 2 promotes disruptio

67 f sphingosine kinase 1 (SphK1) and increases sphingosine 1-phosphate production in adipocytes in a ma

68 While inhibition of sphingosine-1-phosphate production did not alter hBD exp

69 and found that Hdac3 suppression diminished sphingosine-1-phosphate production.

70 lceramide, glucosylsphingosine, sphingosine, sphingosine-1-phosphate) promote alpha-synuclein aggrega

71 lation of CC-chemokine receptor 7 (CCR7) and sphingosine 1- phosphate receptor-1 (S1PR1) expression a

72 Here, we show that the sphingosine 1-phosphate receptor (S1PR) modulator fingol

73 Sphingosine 1-phosphate receptor 1 (S1P1) plays a pivota

74 Sphingosine 1-phosphate receptor 1 (S1P1), a G protein-c

75 Whereas the role of sphingosine 1-phosphate receptor 1 (S1PR1) in T cell egr

76 targets, including the key migratory factor sphingosine 1-phosphate receptor 1 (S1PR1).

77 Endothelial cells were stimulated with sphingosine 1-phosphate receptor 1 agonists to determine

78 th sphingosine 1-phosphate, FTY720, or other sphingosine 1-phosphate receptor 1 agonists.

79 L/6 mice with bleomycin to assess effects of sphingosine 1-phosphate receptor 1 agonists.

80 red mice maintains significantly higher lung sphingosine 1-phosphate receptor 1 expression compared w

81 receptor 1 agonists to determine effects on sphingosine 1-phosphate receptor 1 expression.

82 r-promoting agent that effectively maintains sphingosine 1-phosphate receptor 1 levels and improves o

83 The selective sphingosine 1-phosphate receptor 1 modulator RP101075 im

84 FTY720 (S)-phosphonate maintains endothelial sphingosine 1-phosphate receptor 1 protein expression in

85 e does not induce beta-arrestin recruitment, sphingosine 1-phosphate receptor 1 ubiquitination, and p

86 Reduction of sphingosine 1-phosphate receptor 1 with small interferen

87 Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in developmen

88 Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective

89 Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively

90 Ozanimod is a sphingosine 1-phosphate receptor modulator, which select

91 in-mediated cell growth and survival via the sphingosine 1-phosphate receptor subtype 2 (S1P2) follow

92 ceptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with h

93 the beta2 adrenergic receptor (beta2AR), the sphingosine 1-phosphate receptor-1 (S1P1), or the kappa-

94 gle-cell) and chromatin domains regulated by sphingosine 1-phosphate receptor-1 (S1PR1) in adult mous

95 Sphingosine 1-phosphate receptor-1 (S1PR1) is essential

96 An established role of sphingosine 1-phosphate receptor-1 in T cells is to guid

97 lial sphingosine 1-phosphate signals through sphingosine 1-phosphate receptor-1 to prevent mitochondr

98 adenosine receptors, dopamine receptor, and sphingosine 1-phosphate receptor.

99 contrasting with the proposed access for the sphingosine 1-phosphate receptor.

100 Sphingosine-1 phosphate receptor 1 (S1P1) is critical fo

101 Previously, we showed that levels of sphingosine-1 phosphate receptor 3 (S1PR3) are increased

102 Sphingosine-1 phosphate receptor-1 (S1P(1)) plays fundam

103 cent data have demonstrated the potential of sphingosine-1-phosphate receptor (S1PR) agonism in the t

104 termine the impact of fingolimod (FTY720), a sphingosine-1-phosphate receptor (S1PR) agonist, on 2 mo

105 Sphingosine-1-phosphate receptor (S1PR) agonists have be

106 Sphingosine-1-phosphate receptor (S1PR) modulators provi

107 New sphingosine-1-phosphate receptor (S1PR) modulators with

108 reating multiple sclerosis, is an agonist of sphingosine-1-phosphate receptor (S1PR), which has been

109 iated through S1P binding to specific GPCRs [sphingosine-1-phosphate receptor (S1PR)1-5] and some oth

110 nic lymphocyte accumulation involved reduced sphingosine-1-phosphate receptor 1 (S1P1) expression and

111 Furthermore, deletion of the sphingosine-1-phosphate receptor 1 (S1P1) in these precu

112 und that iNKT cells are divided into CD69(+) sphingosine-1-phosphate receptor 1 (S1P1)(-) tissue resi

113 phingosine-related therapeutics, agonists of sphingosine-1-phosphate receptor 1 (S1P1).

114 by utilizing the clinically important GPCR, sphingosine-1-phosphate receptor 1 (S1P1).

115 or lung migration, they failed to upregulate sphingosine-1-phosphate receptor 1 (S1PR1) and its criti

116 ASM stems from impaired signaling downstream sphingosine-1-phosphate receptor 1 (S1PR1), which normal

117 Lymphocyte sequestration with sphingosine-1-phosphate receptor 1 antagonist FTY720 spe

118 Accordingly, FTY720, a sphingosine-1-phosphate receptor 1 antagonist, failed to

119 S1P1 (sphingosine-1-phosphate receptor 1) agonists prevent lym

120 and tissue retention markers but diminished sphingosine-1-phosphate receptor 1, a receptor that faci

121 lipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1.

122 Here, we find that sphingosine-1-phosphate receptor 2 (S1PR2) acts in a cel

123 neutralizing anti-S1P antibody (mAb) and the sphingosine-1-phosphate receptor 2 (S1PR2) antagonist JT

124 We find that the sphingosine-1-phosphate receptor 2 (S1PR2) is repressed

125 act via HSPGs independently of its receptor, Sphingosine-1-Phosphate receptor 2 (S1PR2).

126 Here we show that the sphingosine-1-phosphate receptor 3 (S1PR3) in the medial

127 Notably, these cells express the sphingosine-1-phosphate receptor 3 (S1PR3), and stimulat

128 strongly support a cardioprotective role for sphingosine-1-phosphate receptor activation during MI.

129 We hypothesized that sphingosine-1-phosphate receptor activation with fingoli

130 Sphingosine-1-phosphate receptor activation with fingoli

131 Fingolimod, a sphingosine-1-phosphate receptor agonist, is used for th

132 We hypothesize that modulation of the sphingosine-1-phosphate receptor by FTY720 would be of t

133 that expression of CD69, by interfering with sphingosine-1-phosphate receptor function, is a critical

134 The sphingosine-1-phosphate receptor modulator, FTY720/fingo

135 th the transcriptional downregulation of the sphingosine-1-phosphate receptor S1P1.

136 Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that i

137 ible mouse model with a temporally disrupted sphingosine-1-phosphate receptor-1 (S1PR1) gene specific

138 clear receptor RORc and an antagonist of the sphingosine-1-phosphate receptor-1-via late-stage methyl

139 Work in mice showed that sphingosine-1-phosphate receptor-2 (S1PR2), a Galpha12 a

140 uencing revealed a Thr289Arg substitution in Sphingosine-1-Phosphate Receptor-2 (S1pr2).

141 lls from lymph nodes in the mouse depends on sphingosine-1-phosphate receptor-3.

142 s such as vasa, pumilio and piwi, as well as sphingosine-1-phosphate receptor.

143 enitor cells (NSCs) in vitro via a PAR1-PAR3-sphingosine-1-phosphate-receptor 1-Akt pathway, which su

144 phate (S1P) is the endogenous ligand for the sphingosine 1-phosphate receptors (S1P1-5) and evokes a

145 Here, we show that retinal endothelial sphingosine 1-phosphate receptors (S1PRs), which restrai

146 The sphingosine-1-phosphate receptors (S1PRs) are a well-stu

147 We observe that CXC chemokine receptor 4 and sphingosine-1-phosphate receptors can form heterodimers

148 This pathway consists of cell-surface sphingosine-1-phosphate receptors, an intracellular casc

149 ation of surface-expressed G protein-coupled sphingosine-1-phosphate receptors.

150 homodimers: the CXC chemokine receptor 4 and sphingosine-1-phosphate receptors.

151 ts toward an important role for the ceramide/sphingosine-1-phosphate rheostat in maintaining lung cel

152 uned by cellular concentrations of SphK1 and sphingosine 1 phosphate (S1P).

153 nase 1 (SPHK1) generates the bioactive lipid sphingosine 1-phosphate (S1P) and has established roles

154 Apolipoprotein M (apoM), a plasma sphingosine 1-phosphate (S1P) carrier, associates with p

155 The chemoattractant sphingosine 1-phosphate (S1P) guides T cell circulation

156 Sphingosine 1-phosphate (S1P) is a bioactive lipid media

157 Sphingosine 1-phosphate (S1P) is a bioactive lipid media

158 Sphingosine 1-phosphate (S1P) is a bioactive lipid that

159 Sphingosine 1-phosphate (S1P) is a bioactive lipid that

160 The bioactive lipid sphingosine 1-phosphate (S1P) is a degradation product o

161 Sphingosine 1-phosphate (S1P) is a lipid mediator formed

162 Sphingosine 1-phosphate (S1P) is a lipid-based signaling

163 Sphingosine 1-phosphate (S1P) is a multifunctional bioac

164 Sphingosine 1-phosphate (S1P) is a pleiotropic bioactive

165 Sphingosine 1-phosphate (S1P) is a pleiotropic signaling

166 Sphingosine 1-phosphate (S1P) is a pleiotropic signaling

167 Sphingosine 1-phosphate (S1P) is a potent vasculoprotect

168 Sphingosine 1-phosphate (S1P) is a sphingolipid and the

169 Elevated sphingosine 1-phosphate (S1P) is detrimental in Sickle C

170 Sphingosine 1-phosphate (S1P) is involved in multiple pa

171 Sphingosine 1-phosphate (S1P) is the endogenous ligand f

172 Here, we show that sphingosine 1-phosphate (S1P) levels are not only increa

173 Sphingosine 1-phosphate (S1P) lyase (SPL) is an intracel

174 Sphingosine 1-phosphate (S1P) lyase has recently been im

175 l compartmentalization of the lipid mediator sphingosine 1-phosphate (S1P) may be one such mechanism.

176 Our previous microarray data indicated sphingosine 1-phosphate (S1P) metabolism and signalling

177 enhances PP2A activity independently of the sphingosine 1-phosphate (S1P) pathway was unknown.

178 The signaling lipid sphingosine 1-phosphate (S1P) plays critical roles in an

179 Sphingosine 1-phosphate (S1P) produces significant endot

180 e kinase 1 (SK1), the enzyme responsible for sphingosine 1-phosphate (S1P) production, is overexpress

181 er (aCKAR), we found that the lipid mediator sphingosine 1-phosphate (S1P) promoted the cellular acti

182 cent data have demonstrated the potential of sphingosine 1-phosphate (S1P) receptor (S1PR) agonism in

183 In this study, we identify the sphingosine 1-phosphate (S1P) receptor 1 (S1P1) as one o

184 eport the BBB-regulatory role of endothelial sphingosine 1-phosphate (S1P) receptor-1, a G protein-co

185 Modulation of sphingosine 1-phosphate (S1P) receptors in a non-selecti

186 trafficking is orchestrated by chemokine and sphingosine 1-phosphate (S1P) receptors that enable homi

187 Here we generated a sphingosine 1-phosphate (S1P) reporter mouse and used th

188 amined how the apolipoprotein M (apoM)-bound sphingosine 1-phosphate (S1P) signaling pathway affects

189 , and lymphatic vessel development, required sphingosine 1-phosphate (S1P) signaling via the G protei

190 Sphingosine 1-phosphate (S1P), a bioactive lipid involve

191 Sphingosine 1-phosphate (S1P), a metabolic product of ce

192 associates with plasma HDL and binds plasma sphingosine 1-phosphate (S1P), a signaling molecule acti

193 lasma membrane, leading to the production of sphingosine 1-phosphate (S1P), ERK1/2 and matriptase act

194 osine kinase 1, which catalyses formation of sphingosine 1-phosphate (S1P), in promoting the differen

195 One of these intermediates, sphingosine 1-phosphate (S1P), is stored at high concent

196 duces the bioactive sphingolipid metabolite, sphingosine 1-phosphate (S1P), plays a critical role in

197 Sphingosine 1-phosphate (S1P), the natural sphingolipid

198 ular thyroid ML-1 cancer cells, sphingolipid sphingosine 1-phosphate (S1P), through S1P receptors 1 a

199 To extrude, a cell produces the lipid, Sphingosine 1-Phosphate (S1P), which activates S1P(2) re

200 S) B cells exhibited enhanced sensitivity to sphingosine 1-phosphate (S1P).

201 gent, thrombin, and barrier-enhancing agent, sphingosine 1-phosphate (S1P).

202 sphingosine kinase 1 (SK1) and its product, sphingosine 1-phosphate (S1P).

203 gosine to the promitogenic/migratory product sphingosine 1-phosphate (S1P).

204 codes a transporter for the signalling lipid sphingosine 1-phosphate (S1P).

205 1 (SK1), a key enzyme in the biosynthesis of sphingosine 1-phosphate (S1P).

206 olipids including ceramides, sphingosine and sphingosine 1-phosphate (S1P).

207 (p < 0.01) Gb3 ganglioside (-50 +/- 3%) and sphingosine 1-phosphate (S1P, -40 +/- 4%), which ended u

208 lymphoid tissues depends on the presence of sphingosine-1 phosphate (S1P) and the regulated expressi

209 The role of sphingosine-1 phosphate (S1P) in leukocyte trafficking h

210 ascular Endothelial Growth Factor (VEGF) and Sphingosine-1 Phosphate (S1P).

211 vestigated the role of the crosstalk between sphingosine-1-phosphate (S1P) and cytokine signaling cas

212 It is an analog of sphingosine-1-phosphate (S1P) and targets S1P receptors

213 The bioactive sphingolipid sphingosine-1-phosphate (S1P) and the kinase that produc

214 though the bioactive sphingolipid metabolite sphingosine-1-phosphate (S1P) and the kinase that produc

215 Serum levels of the lipid mediator sphingosine-1-phosphate (S1P) are reduced in septic pati

216 hat skin mast cell (MC) activation and local sphingosine-1-phosphate (S1P) are significantly augmente

217 We now provide evidence that sphingosine-1-phosphate (S1P) generated in the dorsal ho

218 report a role for HGF-induced intracellular sphingosine-1-phosphate (S1P) generation catalyzed by sp

219 ive immunity and involves chemotaxis along a sphingosine-1-phosphate (S1P) gradient.

220 tissues into the circulation is dependent on sphingosine-1-phosphate (S1P) gradients, sensed by S1P r

221 ansport cells that respond to chemokines and sphingosine-1-phosphate (S1P) gradients.

222 suggesting involvement of phospholipids like sphingosine-1-phosphate (S1P) in AKR1B10's oncogenic fun

223 Apolipoprotein M (ApoM) transports sphingosine-1-phosphate (S1P) in plasma, and ApoM-defici

224 Chronic sphingosine-1-phosphate (S1P) infusion resulted in a dev

225 Sphingosine-1-phosphate (S1P) is a bioactive lipid media

226 Sphingosine-1-phosphate (S1P) is a bioactive lipid that

227 Sphingosine-1-phosphate (S1P) is a bioactive signalling

228 Sphingosine-1-phosphate (S1P) is a bioactive sphingolipi

229 Sphingosine-1-phosphate (S1P) is a bioactive sphingolipi

230 Sphingosine-1-phosphate (S1P) is a constituent of high-d

231 For example, circulating sphingosine-1-phosphate (S1P) is a key regulator of lymp

232 Sphingosine-1-phosphate (S1P) is a lysophospholipid that

233 Sphingosine-1-phosphate (S1P) is emerging as a potent mo

234 Sphingosine-1-phosphate (S1P) is generated through phosp

235 Sphingosine-1-phosphate (S1P) lyase (SPL) irreversibly d

236 nic bone marrow transplantation of inducible sphingosine-1-phosphate (S1P) lyase knockout mice to spe

237 recessive mutations in SGPL1, which encodes sphingosine-1-phosphate (S1P) lyase.

238 The bioactive sphingolipid sphingosine-1-phosphate (S1P) mediates cellular prolifer

239 Sphingosine-1-phosphate (S1P) mediates egress of immune

240 GPCRs for thrombin and sphingosine-1-phosphate (S1P) on human glioblastoma cell

241 concomitantly generates sphingosine used for sphingosine-1-phosphate (S1P) production.

242 Administration of an immunomodulatory sphingosine-1-phosphate (S1P) receptor 1 (S1P1R) agonist

243 Functional sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) antagon

244 Sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) is crit

245 s study, we showed that the egress receptor, sphingosine-1-phosphate (S1P) receptor 1 (S1PR1), was ex

246 Inactivating mutations in the sphingosine-1-phosphate (S1P) receptor 2 (S1PR2) promote

247 ihydrogen phosphate ester) is a nonselective sphingosine-1-phosphate (S1P) receptor agonist thought t

248 gic receptors (ARs) and the cardioprotective sphingosine-1-phosphate (S1P) receptor-1 (S1PR1).

249 We examined the expression and function of sphingosine-1-phosphate (S1P) receptors in human thymocy

250 These results demonstrate a role for sphingosine-1-phosphate (S1P) signaling in B. pertussis-

251 Sphingosine-1-phosphate (S1P) signaling is essential for

252 The oral drug FTY720 affects sphingosine-1-phosphate (S1P) signaling on targeted cell

253 The sphingosine-1-phosphate (S1P) signaling pathway is an at

254 This leads to reduced sphingosine-1-phosphate (S1P) signaling via the S1P rece

255 the elevation of myogenic tone via enhanced sphingosine-1-phosphate (S1P) signaling.

256 The sphingolipid sphingosine-1-phosphate (S1P) signals through five G-pro

257 In vitro, sphingosine-1-phosphate (S1P) stimulates migration of ge

258 Because sphingosine-1-phosphate (S1P) strengthens AJs, we determ

259 Sphingosine-1-phosphate (S1P) strongly activates mouse v

260 tion in pulmonary metastasis was observed in sphingosine-1-phosphate (S1P) transporter spinster homol

261 Ca(2+) mobilization by sphingosine-1-phosphate (S1P) was also attenuated by CFT

262 However, levels of sphingosine-1-phosphate (S1P) were significantly increas

263 Membrane sphingolipids are metabolized to sphingosine-1-phosphate (S1P), a bioactive lipid mediato

264 hingosine kinase-1, an enzyme that generates sphingosine-1-phosphate (S1P), a bioactive lipid mediato

265 osine kinases 1 (SK1) and 2 (SK2) synthesize sphingosine-1-phosphate (S1P), a bioactive lipid messeng

266 Sphingosine-1-phosphate (S1P), a bioactive sphingolipid

267 Sphingosine-1-phosphate (S1P), a bioactive sphingolipid

268 polymerization-promoting cyclic peptide, or sphingosine-1-phosphate (S1P), a follicular fluid consti

269 We evaluated the effect of sphingosine-1-phosphate (S1P), a lipid that is elevated

270 othelial barrier-protective bioactive lipid, sphingosine-1-phosphate (S1P), could ameliorate the micr

271 A bioactive lipid, sphingosine-1-phosphate (S1P), has been suggested to aff

272 the native state, but can be metabolized to sphingosine-1-phosphate (S1P), linked to inflammation an

273 pathology, we investigated the metabolism of Sphingosine-1-phosphate (S1P), one of the most important

274 membranes, sphingolipid metabolites, such as sphingosine-1-phosphate (S1P), play important roles as s

275 yonic pancreata, and genomics, we found that sphingosine-1-phosphate (S1p), signalling through the G

276 Th17 cells stimulated with cl-CD95L produced sphingosine-1-phosphate (S1P), which promoted endothelia

277 n endoplasmic reticulum (ER) stress-mediated sphingosine-1-phosphate (S1P)- dependent mechanism of CA

278 both mTORC1-dependent cell proliferation and sphingosine-1-phosphate (S1P)-dependent entosis and apic

279 ble cleavage of the lipid-signaling molecule sphingosine-1-phosphate (S1P).

280 tive lipids, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P).

281 nuclear sphingolipid metabolite to generate sphingosine-1-phosphate (S1P).

282 sine producing the potent signaling molecule sphingosine-1-phosphate (S1P).

283 high-density lipoprotein (HDL) particles and sphingosine-1-phosphate (S1P).

284 ine accumulation and reduced levels of brain sphingosine-1-phosphate (S1P).

285 iator and G protein-coupled receptor agonist sphingosine-1-phosphate (S1P).

286 om the action of its phosphate metabolite on sphingosine-1-phosphate S1P1 receptors, while a variety

287 Sphingosine 1-phosphate signaling induces SNAI2 expressi

288 te the thymic and lymph node egress defects, sphingosine-1-phosphate signaling was not obviously pert

289 S1P (Sphingosine 1-phosphate) signaling coordinates vascular

290 . (2017) now show that lymphatic endothelial sphingosine 1-phosphate signals through sphingosine 1-ph

291 Sphingosine 1-phosphate (SP1) receptors may be attractiv

292 rominent sphingolipids include ceramides and sphingosine-1-phosphate that regulate multiple aspects o

293 ed TAZ activity upon a second stimulus (i.e. sphingosine 1-phosphate) that induced nuclear TAZ transl

294 laimed that TRAF2 RING requires a co-factor, sphingosine-1-phosphate, that is generated by the enzyme

295 thesis of a series of vinylated analogues of sphingosine-1-phosphate together with their unambiguous

296 e of a reporter for the signaling lipid S1P (sphingosine 1-phosphate), we found that cells sensed hig

297 levels of ceramides and the immune mediator sphingosine-1-phosphate were also observed.

298 of bioactive lysophosphatidic acid (LPA) and sphingosine 1 phosphate, which likely explains its role

299 al cells, promoting synthesis and release of sphingosine-1 phosphate, which inhibits trafficking of T

300 ch disrupt endothelial barrier function, and sphingosine-1-phosphate, which stabilizes barrier functi